memantine in the treatment of schizophrenia

The effect of Memantine on negative symptoms in patients with chronic schizophrenia: a double blind and placebo controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138902241556N13

Enrollment

Registered

2010-05-20

Start date

2010-06-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. Schizophrenia

Interventions

Placebo

Tablet Risperidone (6 mg/day) combined with 5 to 20 mg/day of Tablets memantin as intervention group for 8 weeks

Intervention 1: Tablet Risperidone (6 mg/day) combined with 5 to 20 mg/day of Tablets memantin as intervention group for 8 weeks. Intervention 2: Tablets Risperidone (6 mg/day) combined with Tablets p

Treatment - Drugs

Tablets Risperidone (6 mg/day) combined with Tablets placebo as control group for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Age between 18-55, Diagnosis of Schizophrenia based on DSM IV 3 chronic Schizophrenia, Minimum Score of 60 on Positive and Negative Scale- Exclusion Criteria:1- Substance dependence,2- IQ <70,3-any other mental disorder on axis I, 4-Any serious medical or neurological problem ,5- receiving oral antipsychotic medications during the last week or receiving any depot antipsychotic medication during the last month,6- receiving ECT during the last 14 days,7- hypersensitivity to memantin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026